EGFR and cancer: The clinical success of oncogene-targeted therapy in specific subsets of patients with lung cancer, such as those with activating mutations in the epidermal growth factor receptor (EGFR), has heralded a new era of precision medicine for cancer that holds great promise for improving patient survival and quality of life [5–10].